ArticleAmerican journal of translational research2026
The adjunctive use of Bifidobacterium Quadruple Viable Bacteria with interferon in pediatric acute enteritis: inhibition of gut hormones, pain mediators, and systemic inflammation.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the adjunctive efficacy of Bifidobacterium Quadruple Viable Bacteria combined with recombinant human interferon α1b in pediatric acute enteritis (PAE).
methodsThis retrospective propensity score matching (PSM) analysis included children aged 1-6 years with PAE admitted from March 2024 to March 2025. Patients receiving conventional therapy alone were assigned to the control group, while those receiving Bifidobacterium Quadruple Viable Bacteria plus recombinant human interferon α1b on the basis of conventional therapy were assigned to the observation group. A total of 128 children were included, with 64 cases in each group. Serum gut hormones, intestinal barrier markers, pain mediators, inflammatory factors, and oxidative stress indicators were compared before and after treatment.
resultsAfter treatment, the observation group showed greater reductions in motilin and gastrin and a more marked increase in somatostatin than the control group. Substance P (SP) and prostaglandin E2 (PGE2) were also lower in the observation group, indicating reduced pain mediator release. In addition, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein (hs-CRP) declined more prominently, while superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) increased and malondialdehyde (MDA) decreased more substantially, suggesting alleviation of systemic inflammation and oxidative stress.
conclusionIn this retrospective PSM analysis, Bifidobacterium Quadruple Viable Bacteria combined with interferon α1b improved gut hormone balance, intestinal barrier function, pain-related mediators, inflammatory responses, and oxidative stress in PAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.